News
Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback